White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome
Mohamed A, do Campo J, Del Fante P, Kwiatek R, Calhoun V, Shan Z. White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome. Fatigue Biomedicine Health & Behavior 2024, ahead-of-print: 1-11. DOI: 10.1080/21641846.2024.2367921.Peer-Reviewed Original ResearchMyalgic encephalomyelitis/chronic fatigue syndromeLow-dose naltrexoneFatigue syndromeWhite-matter tractsPre-treatment baselineDebilitating chronic illnessDeficit symptomsME/CFS patientsDiffusion-weighted imaging dataReducing depressionTreating ME/CFSSymptom improvementFractional anisotropyOff-label treatmentWhite-matter changesNaltrexoneNICE guidelinesPost-treatmentSymptomsME/CFSNeuroimaging characteristicsClinical measuresChronic illnessControl groupRandomized controlled trialsOral ketamine effects on dynamics of functional network connectivity in patients treated for chronic suicidality
Shan Z, Can A, Mohamed A, Dutton M, Hermens D, Calhoun V, Williams L, Bennett M, Lagopoulos J. Oral ketamine effects on dynamics of functional network connectivity in patients treated for chronic suicidality. European Archives Of Psychiatry And Clinical Neuroscience 2024, 1-11. PMID: 38772940, DOI: 10.1007/s00406-024-01831-x.Peer-Reviewed Original ResearchBeck Scale for Suicide IdeationBeck Scale for Suicidal Ideation scoresChronic suicidalityFollow-upPersistent respondingScale for Suicide IdeationCognitive control statesBrain statesSuicide-preventive effectsResting-state functional MRIMechanisms of ketamineDynamic functional connectivity analysisFunctional network connectivityPost-treatment patientsCharacteristics of patientsTrial's primary endpointPost-treatmentKetamine trialsBrain mechanismsKetamine effectsKetamine treatmentSuicidal ideationBrain changesFunctional MRIPrimary endpoint